- Home
- PSTX vs CAPR Comparison
PSTX vs CAPR Comparison
Compare PSTX & CAPR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PSTX
- CAPR
- Stock Information
- Founded
- PSTX 2014
- CAPR 2005
- Country
- PSTX United States
- CAPR United States
- Employees
- PSTX N/A
- CAPR N/A
- Industry
- PSTX Biotechnology: Biological Products (No Diagnostic Substances)
- CAPR Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- PSTX Health Care
- CAPR Health Care
- Exchange
- PSTX Nasdaq
- CAPR Nasdaq
- Market Cap
- PSTX 909.4M
- CAPR 867.6M
- IPO Year
- PSTX 2020
- CAPR N/A
- Fundamental
- Price
- PSTX $9.45
- CAPR $13.07
- Analyst Decision
- PSTX Hold
- CAPR Strong Buy
- Analyst Count
- PSTX 3
- CAPR 7
- Target Price
- PSTX $9.00
- CAPR $39.29
- AVG Volume (30 Days)
- PSTX 2.7M
- CAPR 1.8M
- Earning Date
- PSTX 11-07-2024
- CAPR 11-13-2024
- Dividend Yield
- PSTX N/A
- CAPR N/A
- EPS Growth
- PSTX N/A
- CAPR N/A
- EPS
- PSTX N/A
- CAPR N/A
- Revenue
- PSTX $150,858,000.00
- CAPR $23,228,045.00
- Revenue This Year
- PSTX $131.92
- CAPR N/A
- Revenue Next Year
- PSTX N/A
- CAPR $74.85
- P/E Ratio
- PSTX N/A
- CAPR N/A
- Revenue Growth
- PSTX 203.18
- CAPR 65.33
- 52 Week Low
- PSTX $1.87
- CAPR $3.52
- 52 Week High
- PSTX $9.58
- CAPR $23.40
- Technical
- Relative Strength Index (RSI)
- PSTX 86.05
- CAPR 37.42
- Support Level
- PSTX $9.35
- CAPR $12.25
- Resistance Level
- PSTX $9.56
- CAPR $20.75
- Average True Range (ATR)
- PSTX 0.10
- CAPR 1.62
- MACD
- PSTX -0.17
- CAPR -0.24
- Stochastic Oscillator
- PSTX 56.67
- CAPR 9.65
About PSTX Poseida Therapeutics Inc.
Poseida Therapeutics Inc is a clinical-stage biopharmaceutical company focused on leveraging non-viral gene engineering technologies to create life-saving therapeutics for patients with a high unmet medical need. It has built a pipeline of autologous and allogeneic chimeric antigen receptor T cell, or CAR-T, product candidates, initially focused on the treatment of hematological malignancies and solid tumours.
About CAPR Capricor Therapeutics Inc.
Capricor Therapeutics Inc is a biotechnology company focused on advancing transformative cell and exosome-based therapeutics to redefine the treatment landscape for rare diseases. The company's product pipeline includes CAP-1002, deramiocel an allogeneic cardiac-derived cell therapy. Deramiocel is currently advancing through Phase 3 clinical development for the treatment of Duchenne muscular dystrophy. Through its proprietary StealthXTM platform, the group uses its exosome technology to conduct preclinical research focused on vaccinology, delivering oligonucleotides, proteins, and small molecules to treat and prevent a wide range of diseases with targeted delivery.